{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:40:19Z","timestamp":1790707219699,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 107-2320-B-038-044-MY3"],"award-info":[{"award-number":["MOST 107-2320-B-038-044-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 107-2320-B-038-044-MY3"],"award-info":[{"award-number":["MOST 107-2320-B-038-044-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 107-2320-B-038-044-MY3"],"award-info":[{"award-number":["MOST 107-2320-B-038-044-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 108-2320-B-038-037-MY3"],"award-info":[{"award-number":["MOST 108-2320-B-038-037-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Education in Taiwan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acute leukemia is a highly heterogeneous disease; therefore, combination therapy is commonly used for patient treatment. Drug\u2013drug interaction is a major concern of combined therapy; hence, dual\/multi-target inhibitors have become a dominant approach for cancer drug development. HDACs and HSP90 are involved in the activation of various oncogenic signaling pathways, including PI3K\/AKT\/mTOR, JAK\/STAT, and RAF\/MEK\/ERK, which are also highly enriched in acute leukemia gene expression profiles. Therefore, we suggest that dual HDAC and HSP90 inhibitors could represent a novel therapeutic approach for acute leukemia. MPT0G449 is a dual effect inhibitor, and it showed cytotoxic effectiveness in acute leukemia cells. Molecular docking analysis indicated that MPT0G449 possessed dual HDAC and HSP90 inhibitory abilities. Furthermore, MPT0G449 induced G<jats:sub>2<\/jats:sub> arrest and caspase-mediated cell apoptosis in acute leukemia cells. The oncogenic signaling molecules AKT, mTOR, STAT3, STAT5, MEK, and ERK were significantly downregulated after MPT0G449 treatment in HL-60 and MOLT-4 cells. In vivo xenograft models confirmed the antitumor activity and showed the upregulation of acetyl-histone H3 and HSP70, biomarkers of pan-HDAC and HSP90 inhibition, with MPT0G449 treatment. These findings suggest that the dual inhibition of HDAC and HSP90 can suppress the expression of oncogenic pathways in acute leukemia, and MPT0G449 represents a novel therapeutic for anticancer treatment.<\/jats:p>","DOI":"10.1038\/s41389-021-00331-0","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T14:03:27Z","timestamp":1620914607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6625-0630","authenticated-orcid":false,"given":"Yi-Wen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9122-3415","authenticated-orcid":false,"given":"Min-Wu","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huang-Ju","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-3848","authenticated-orcid":false,"given":"Liang-Chieh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ping","family":"Liou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ron","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Chung","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-9121","authenticated-orcid":false,"given":"Wei-Chun","family":"HuangFu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7449-3539","authenticated-orcid":false,"given":"Shiow-Lin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"331_CR1","doi-asserted-by":"publisher","first-page":"e2014075","DOI":"10.4084\/mjhid.2014.075","volume":"6","author":"MI Del Principe","year":"2014","unstructured":"Del Principe, M. I. et al. Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy. Mediterr. J. Hematol. Infect. Dis. 6, e2014075 (2014).","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"331_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejmech.2017.05.016","volume":"136","author":"RG Fu","year":"2017","unstructured":"Fu, R. G., Sun, Y., Sheng, W. B. & Liao, D. F. Designing multi-targeted agents: an emerging anticancer drug discovery paradigm. Eur. J. Med. Chem. 136, 195\u2013211 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"331_CR3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute myeloid leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"331_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/17460441.2018.1413089","volume":"13","author":"B Ravikumar","year":"2018","unstructured":"Ravikumar, B. & Aittokallio, T. Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery. Expert Opin. Drug Discov. 13, 179\u2013192 (2018).","journal-title":"Expert Opin. Drug Discov."},{"key":"331_CR5","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","volume":"143","author":"NM Raghavendra","year":"2018","unstructured":"Raghavendra, N. M. et al. Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur. J. Med. Chem. 143, 1277\u20131300 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"331_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1127-7","volume":"19","author":"P Wang","year":"2020","unstructured":"Wang, P., Wang, Z. & Liu, J. Role of HDACs in normal and malignant hematopoiesis. Mol. Cancer 19, 5 (2020).","journal-title":"Mol. Cancer"},{"key":"331_CR7","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1182\/blood-2013-03-488114","volume":"123","author":"M Bots","year":"2014","unstructured":"Bots, M. et al. Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood 123, 1341\u20131352 (2014).","journal-title":"Blood"},{"key":"331_CR8","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2015-03-632984","volume":"126","author":"GM Matthews","year":"2015","unstructured":"Matthews, G. M. et al. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood 126, 2392\u20132403 (2015).","journal-title":"Blood"},{"key":"331_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/bjc.2016.36","volume":"114","author":"E Ceccacci","year":"2016","unstructured":"Ceccacci, E. & Minucci, S. Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia. Br. J. Cancer 114, 605\u2013611 (2016).","journal-title":"Br. J. Cancer"},{"key":"331_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-017-0463-6","volume":"10","author":"C Saygin","year":"2017","unstructured":"Saygin, C. & Carraway, H. E. Emerging therapies for acute myeloid leukemia. J. Hematol. Oncol. 10, 93 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"331_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fonc.2018.00092","volume":"8","author":"A Suraweera","year":"2018","unstructured":"Suraweera, A., O\u2019Byrne, K. J. & Richard, D. J. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front. Oncol. 8, 92 (2018).","journal-title":"Front. Oncol."},{"key":"331_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1158\/1055-9965.EPI-06-1069","volume":"16","author":"B Krishnan","year":"2007","unstructured":"Krishnan, B. & Morgan, G. J. Non-Hodgkin lymphoma secondary to cancer chemotherapy. Cancer Epidemiol. Biomark. Prev. 16, 377\u2013380 (2007).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"331_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/ajco.12698","volume":"13","author":"K Roberts","year":"2017","unstructured":"Roberts, K. et al. Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities. Asia Pac. J. Clin. Oncol. 13, 277\u2013288 (2017).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"331_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc1716","volume":"5","author":"L Whitesell","year":"2005","unstructured":"Whitesell, L. & Lindquist, S. L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5, 761\u2013772 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"331_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrm.2017.20","volume":"18","author":"FH Schopf","year":"2017","unstructured":"Schopf, F. H., Biebl, M. M. & Buchner, J. The HSP90 chaperone machinery. Nat. Rev. Mol. Cell Biol. 18, 345\u2013360 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"331_CR16","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.3390\/ijms19092560","volume":"19","author":"A Hoter","year":"2018","unstructured":"Hoter, A., El-Sabban, M. E. & Naim, H. Y. The HSP90 Family: structure, regulation, function, and implications in health and disease. Int J. Mol. Sci. 19, 2560 (2018).","journal-title":"Int J. Mol. Sci."},{"key":"331_CR17","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/sj.bjc.6605066","volume":"100","author":"D Mahalingam","year":"2009","unstructured":"Mahalingam, D. et al. Targeting HSP90 for cancer therapy. Br. J. Cancer 100, 1523\u20131529 (2009).","journal-title":"Br. J. Cancer"},{"key":"331_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-7-17","volume":"7","author":"N Schoof","year":"2009","unstructured":"Schoof, N., von Bonin, F., Trumper, L. & Kube, D. HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells. Cell Commun. Signal. 7, 17 (2009).","journal-title":"Cell Commun. Signal."},{"key":"331_CR19","first-page":"1544","volume":"7","author":"T Huang","year":"2014","unstructured":"Huang, T. et al. Expression of Hsp90alpha and cyclin B1 were related to prognosis of esophageal squamous cell carcinoma and keratin pearl formation. Int J. Clin. Exp. Pathol. 7, 1544\u20131552 (2014).","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"331_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.gene.2014.03.046","volume":"542","author":"WL Tian","year":"2014","unstructured":"Tian, W. L. et al. High expression of heat shock protein 90 alpha and its significance in human acute leukemia cells. Gene 542, 122\u2013128 (2014).","journal-title":"Gene"},{"key":"331_CR21","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/annonc\/mdm545","volume":"19","author":"MM McCarthy","year":"2008","unstructured":"McCarthy, M. M. et al. HSP90 as a marker of progression in melanoma. Ann. Oncol. 19, 590\u2013594 (2008).","journal-title":"Ann. Oncol."},{"key":"331_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.bcmd.2012.11.002","volume":"50","author":"M Zackova","year":"2013","unstructured":"Zackova, M. et al. Hsp90 - a potential prognostic marker in CML. Blood Cells Mol. Dis. 50, 184\u2013189 (2013).","journal-title":"Blood Cells Mol. Dis."},{"key":"331_CR23","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.taap.2013.09.018","volume":"273","author":"D Zhou","year":"2013","unstructured":"Zhou, D. et al. A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors. Toxicol. Appl Pharmacol. 273, 401\u2013409 (2013).","journal-title":"Toxicol. Appl Pharmacol."},{"key":"331_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-08-0132","volume":"15","author":"U Banerji","year":"2009","unstructured":"Banerji, U. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res. 15, 9\u201314 (2009).","journal-title":"Clin. Cancer Res."},{"key":"331_CR25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2174\/156802609789895728","volume":"9","author":"YS Kim","year":"2009","unstructured":"Kim, Y. S. et al. Update on Hsp90 inhibitors in clinical trial. Curr. Top. Med. Chem. 9, 1479\u20131492 (2009).","journal-title":"Curr. Top. Med. Chem."},{"key":"331_CR26","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.leukres.2011.05.014","volume":"35","author":"W Yu","year":"2011","unstructured":"Yu, W. et al. Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor. Leuk. Res. 35, 1212\u20131218 (2011).","journal-title":"Leuk. Res."},{"key":"331_CR27","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","volume":"105","author":"P George","year":"2005","unstructured":"George, P. et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105, 1768\u20131776 (2005).","journal-title":"Blood"},{"key":"331_CR28","doi-asserted-by":"publisher","first-page":"794901","DOI":"10.1155\/2009\/794901","volume":"2009","author":"A Nguyen","year":"2009","unstructured":"Nguyen, A. et al. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma 2009, 794901 (2009).","journal-title":"Sarcoma"},{"key":"331_CR29","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.bcp.2011.11.011","volume":"83","author":"X Lu","year":"2012","unstructured":"Lu, X., Xiao, L., Wang, L. & Ruden, D. M. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs. Biochem. Pharmacol. 83, 995\u20131004 (2012).","journal-title":"Biochem. Pharmacol."},{"key":"331_CR30","doi-asserted-by":"publisher","first-page":"111725","DOI":"10.1016\/j.ejmech.2019.111725","volume":"185","author":"S Mehndiratta","year":"2020","unstructured":"Mehndiratta, S. et al. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-gamma induced PD-L1 expression. Eur. J. Med. Chem. 185, 111725 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"331_CR31","first-page":"346","volume":"14","author":"S Chatterjee","year":"2016","unstructured":"Chatterjee, S., Bhattacharya, S., Socinski, M. A. & Burns, T. F. HSP90 inhibitors in lung cancer: promise still unfulfilled. Clin. Adv. Hematol. Oncol. 14, 346\u2013356 (2016).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"331_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/1078-0432.CCR-14-0979","volume":"21","author":"GI Shapiro","year":"2015","unstructured":"Shapiro, G. I. et al. First-in-human phase I dose escalation study of a second-generation non-ansamycin HSP90 inhibitor, AT13387, in patients with advanced solid tumors. Clin. Cancer Res. 21, 87\u201397 (2015).","journal-title":"Clin. Cancer Res."},{"key":"331_CR33","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/med.21437","volume":"37","author":"C Zagni","year":"2017","unstructured":"Zagni, C., Floresta, G., Monciino, G. & Rescifina, A. The search for potent, small-molecule HDACIs in cancer treatment: a decade after vorinostat. Med. Res. Rev. 37, 1373\u20131428 (2017).","journal-title":"Med. Res. Rev."},{"key":"331_CR34","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrd4579","volume":"14","author":"KJ Falkenberg","year":"2015","unstructured":"Falkenberg, K. J. & Johnstone, R. W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders (vol 13, pg 673, 2014). Nat. Rev. Drug Discov. 14, 219 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"331_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1196\/annals.1391.012","volume":"1113","author":"P Workman","year":"2007","unstructured":"Workman, P., Burrows, F., Neckers, L. & Rosen, N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. N. Y Acad. Sci. 1113, 202\u2013216 (2007).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"331_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1172\/JCI69738","volume":"124","author":"AC West","year":"2014","unstructured":"West, A. C. & Johnstone, R. W. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30\u201339 (2014).","journal-title":"J. Clin. Invest."},{"key":"331_CR37","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1038\/sj.onc.1210610","volume":"26","author":"MA Glozak","year":"2007","unstructured":"Glozak, M. A. & Seto, E. Histone deacetylases and cancer. Oncogene 26, 5420\u20135432 (2007).","journal-title":"Oncogene"},{"key":"331_CR38","doi-asserted-by":"publisher","first-page":"8033","DOI":"10.1128\/MCB.19.12.8033","volume":"19","author":"S Bharadwaj","year":"1999","unstructured":"Bharadwaj, S., Ali, A. & Ovsenek, N. Multiple components of the HSP90 chaperone complex function in regulation of heat shock factor 1 in vivo. Mol. Cell Biol. 19, 8033\u20138041 (1999).","journal-title":"Mol. Cell Biol."},{"key":"331_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/13547500903261347","volume":"15","author":"N Dakappagari","year":"2010","unstructured":"Dakappagari, N. et al. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors. Biomarkers 15, 31\u201338 (2010).","journal-title":"Biomarkers"},{"key":"331_CR40","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.dnarep.2006.05.011","volume":"5","author":"PA Jeggo","year":"2006","unstructured":"Jeggo, P. A. & Lobrich, M. Contribution of DNA repair and cell cycle checkpoint arrest to the maintenance of genomic stability. DNA Repair 5, 1192\u20131198 (2006).","journal-title":"DNA Repair"},{"key":"331_CR41","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1158\/1078-0432.CCR-16-2172","volume":"23","author":"A Derakhshan","year":"2017","unstructured":"Derakhshan, A., Chen, Z. & Van Waes, C. Therapeutic small molecules target inhibitor of apoptosis proteins in cancers with deregulation of extrinsic and intrinsic cell death pathways. Clin. Cancer Res. 23, 1379\u20131387 (2017).","journal-title":"Clin. Cancer Res."},{"key":"331_CR42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/j.1365-2184.2012.00845.x","volume":"45","author":"L Ouyang","year":"2012","unstructured":"Ouyang, L. et al. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 45, 487\u2013498 (2012).","journal-title":"Cell Prolif."},{"key":"331_CR43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-genet-102108-134850","volume":"43","author":"C Wang","year":"2009","unstructured":"Wang, C. & Youle, R. J. The role of mitochondria in apoptosis*. Annu. Rev. Genet. 43, 95\u2013118 (2009).","journal-title":"Annu. Rev. Genet."},{"key":"331_CR44","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nrc2663","volume":"9","author":"TG Cotter","year":"2009","unstructured":"Cotter, T. G. Apoptosis and cancer: the genesis of a research field. Nat. Rev. Cancer 9, 501\u2013507 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"331_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40591-015-0040-8","volume":"3","author":"L Fransecky","year":"2015","unstructured":"Fransecky, L., Mochmann, L. H. & Baldus, C. D. Outlook on PI3K\/AKT\/mTOR inhibition in acute leukemia. Mol. Cell Ther. 3, 2 (2015).","journal-title":"Mol. Cell Ther."},{"key":"331_CR46","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3324\/haematol.2013.098442","volume":"99","author":"S Bibi","year":"2014","unstructured":"Bibi, S. et al. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica 99, 417\u2013429 (2014).","journal-title":"Haematologica"},{"key":"331_CR47","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1053\/j.seminoncol.2008.04.004","volume":"35","author":"C Scholl","year":"2008","unstructured":"Scholl, C., Gilliland, D. G. & Frohling, S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol. 35, 336\u2013345 (2008).","journal-title":"Semin Oncol."},{"key":"331_CR48","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1074\/mcp.M112.017483","volume":"11","author":"MP Alcolea","year":"2012","unstructured":"Alcolea, M. P. et al. Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol. Cell Proteom. 11, 453\u2013466 (2012).","journal-title":"Mol. Cell Proteom."},{"key":"331_CR49","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/leu.2011.66","volume":"25","author":"LS Steelman","year":"2011","unstructured":"Steelman, L. S. et al. Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy. Leukemia 25, 1080\u20131094 (2011).","journal-title":"Leukemia"},{"key":"331_CR50","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"331_CR51","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","volume":"126","author":"MR Litzow","year":"2015","unstructured":"Litzow, M. R. & Ferrando, A. A. How I treat T-cell acute lymphoblastic leukemia in adults. Blood 126, 833\u2013841 (2015).","journal-title":"Blood"},{"key":"331_CR52","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1172\/JCI61269","volume":"122","author":"P Van Vlierberghe","year":"2012","unstructured":"Van Vlierberghe, P. & Ferrando, A. The molecular basis of T cell acute lymphoblastic leukemia. J. Clin. Invest. 122, 3398\u20133406 (2012).","journal-title":"J. Clin. Invest."},{"key":"331_CR53","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.euroneuro.2009.04.003","volume":"19","author":"G Goodwin","year":"2009","unstructured":"Goodwin, G. et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP consensus meeting, March 2008, Nice. Eur. Neuropsychopharmacol. 19, 520\u2013532 (2009).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"331_CR54","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","volume":"171","author":"AC Palmer","year":"2017","unstructured":"Palmer, A. C. & Sorger, P. K. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 171, 1678\u201391 e13 (2017).","journal-title":"Cell"},{"key":"331_CR55","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00228-015-1967-z","volume":"72","author":"S Mu","year":"2016","unstructured":"Mu, S. et al. Panobinostat PK\/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed\/refractory multiple myeloma. Eur. J. Clin. Pharmacol. 72, 153\u2013161 (2016).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"331_CR56","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/00498254.2016.1184356","volume":"47","author":"NR Srinivas","year":"2017","unstructured":"Srinivas, N. R. Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives. Xenobiotica 47, 354\u2013368 (2017).","journal-title":"Xenobiotica"},{"key":"331_CR57","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/leu.2015.180","volume":"30","author":"H Wu","year":"2016","unstructured":"Wu, H. et al. Discovery of a BTK\/MNK dual inhibitor for lymphoma and leukemia. Leukemia 30, 173\u2013181 (2016).","journal-title":"Leukemia"},{"key":"331_CR58","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1016\/j.bmcl.2016.10.087","volume":"26","author":"B Lam","year":"2016","unstructured":"Lam, B. et al. Discovery of TAK-659 an orally available investigational inhibitor of spleen tyrosine kinase (SYK). Bioorg. Med. Chem. Lett. 26, 5947\u20135950 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"331_CR59","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1021\/acschembio.6b01014","volume":"12","author":"J Iaconelli","year":"2017","unstructured":"Iaconelli, J. et al. Lysine deacetylation by HDAC6 regulates the kinase activity of AKT in human neural progenitor cells. ACS Chem. Biol. 12, 2139\u20132148 (2017).","journal-title":"ACS Chem. Biol."},{"key":"331_CR60","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1038\/leu.2017.130","volume":"31","author":"J Long","year":"2017","unstructured":"Long, J. et al. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia 31, 2761\u20132770 (2017).","journal-title":"Leukemia"},{"key":"331_CR61","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/leu.2011.340","volume":"26","author":"M Gupta","year":"2012","unstructured":"Gupta, M. et al. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 26, 1356\u20131364 (2012).","journal-title":"Leukemia"},{"key":"331_CR62","doi-asserted-by":"publisher","first-page":"e19798","DOI":"10.1371\/journal.pone.0019798","volume":"6","author":"J Zhou","year":"2011","unstructured":"Zhou, J. et al. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PloS ONE 6, e19798 (2011).","journal-title":"PloS ONE"},{"key":"331_CR63","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1158\/0008-5472.CAN-07-6091","volume":"68","author":"VR Fantin","year":"2008","unstructured":"Fantin, V. R. et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 68, 3785\u20133794 (2008).","journal-title":"Cancer Res."},{"key":"331_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.98","volume":"5","author":"S Mithraprabhu","year":"2014","unstructured":"Mithraprabhu, S., Khong, T. & Spencer, A. Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton. Cell Death Dis. 5, e1134 (2014).","journal-title":"Cell Death Dis."},{"key":"331_CR65","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1182\/blood-2012-08-449140","volume":"121","author":"AR Chakraborty","year":"2013","unstructured":"Chakraborty, A. R. et al. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood 121, 4115\u20134125 (2013).","journal-title":"Blood"},{"key":"331_CR66","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.bbrc.2013.03.009","volume":"433","author":"T Sakamoto","year":"2013","unstructured":"Sakamoto, T. et al. Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models. Biochem Biophys. Res. Commun. 433, 456\u2013462 (2013).","journal-title":"Biochem Biophys. Res. Commun."},{"key":"331_CR67","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4062\/biomolther.2019.051","volume":"27","author":"S Park","year":"2019","unstructured":"Park, S., Park, J. A., Jeon, J. H. & Lee, Y. Traditional and novel mechanisms of heat shock protein 90 (HSP90) inhibition in cancer chemotherapy including HSP90 cleavage. Biomol. Ther. 27, 423\u2013434 (2019).","journal-title":"Biomol. Ther."},{"key":"331_CR68","doi-asserted-by":"publisher","first-page":"e18552","DOI":"10.1371\/journal.pone.0018552","volume":"6","author":"DA Proia","year":"2011","unstructured":"Proia, D. A. et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK\/STAT signaling. PloS ONE 6, e18552 (2011).","journal-title":"PloS ONE"},{"key":"331_CR69","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/ncb1131","volume":"6","author":"BK Eustace","year":"2004","unstructured":"Eustace, B. K. et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol. 6, 507\u2013514 (2004).","journal-title":"Nat. Cell Biol."},{"key":"331_CR70","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1182\/blood-2007-10-116319","volume":"112","author":"W Fiskus","year":"2008","unstructured":"Fiskus, W. et al. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 112, 2896\u20132905 (2008).","journal-title":"Blood"},{"key":"331_CR71","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.3390\/molecules20033898","volume":"20","author":"M Mottamal","year":"2015","unstructured":"Mottamal, M., Zheng, S., Huang, T. L. & Wang, G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 20, 3898\u20133941 (2015).","journal-title":"Molecules"},{"key":"331_CR72","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1158\/1535-7163.MCT-06-0418","volume":"5","author":"W Fiskus","year":"2006","unstructured":"Fiskus, W. et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol. Cancer Ther. 5, 3096\u20133104 (2006).","journal-title":"Mol. Cancer Ther."},{"key":"331_CR73","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1097\/CAD.0000000000000122","volume":"25","author":"J Savickiene","year":"2014","unstructured":"Savickiene, J. et al. Epigenetic and molecular mechanisms underlying the antileukemic activity of the histone deacetylase inhibitor belinostat in human acute promyelocytic leukemia cells. Anticancer Drugs 25, 938\u2013949 (2014).","journal-title":"Anticancer Drugs"},{"key":"331_CR74","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-08-0721","volume":"14","author":"W Fiskus","year":"2008","unstructured":"Fiskus, W. et al. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin. Cancer Res. 14, 6106\u20136115 (2008).","journal-title":"Clin. Cancer Res."},{"key":"331_CR75","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-015-0176-7","volume":"8","author":"MW Chao","year":"2015","unstructured":"Chao, M. W. et al. The synergic effect of vincristine and vorinostat in leukemia in vitro and in vivo. J. Hematol. Oncol. 8, 82 (2015).","journal-title":"J. Hematol. Oncol."},{"key":"331_CR76","unstructured":"LeadIT, B. http:\/\/www.biosolveit.de\/LeadIT (2011)"},{"key":"331_CR77","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. et al. The Protein Data Bank. Nucleic Acids Res. 28, 235\u2013242 (2000).","journal-title":"Nucleic Acids Res."}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-021-00331-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-021-00331-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-021-00331-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T15:35:18Z","timestamp":1669822518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-021-00331-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":77,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["331"],"URL":"https:\/\/doi.org\/10.1038\/s41389-021-00331-0","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,13]]},"assertion":[{"value":"13 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"39"}}